ResearcherUniversity Medical Center Hamburg-EppendorfActive in the last 2 years
Christine Nitschke
Matched on ORCID iD 0000-0002-4645-7909; OpenAlex author ID A5064556596. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 2 papers
Papers 7
- Patient-derived tumor organoids highlight the potential of precision medicine in managing pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.35443↗
- Identification and characterization of tumor and stromal derived liquid biopsy analytes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03262-x↗
- Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1093/clinchem/hvac214↗
- Tumor-Stroma Interaction in PDAC as a New Approach for Liquid Biopsy and its Potential Clinical Implications. First author DOI 10.3389/fcell.2022.918795↗
- Circulating Cancer Associated Macrophage-like Cells as a Potential New Prognostic Marker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/biomedicines10112955↗
- Characterization of RARRES1 Expression on Circulating Tumor Cells as Unfavorable Prognostic Marker in Resected Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/cancers14184405↗
- A novel risk-scoring system conducing to chemotherapy decision for patients with pancreatic ductal adenocarcinoma after pancreatectomy. Co-author DOI 10.7150/jca.57768↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Harriet Wikman · 6 shared papers, 2022–2025 · strength 0.99
- Paper Patient-derived tumor organoids highlight the potential of precision medicine in managing pancreatic ductal adenocarcin… DOI 10.1002/ijc.35443↗
- Paper Identification and characterization of tumor and stromal derived liquid biopsy analytes in pancreatic ductal adenocarci… DOI 10.1186/s13046-024-03262-x↗
- Paper Tumor-Stroma Interaction in PDAC as a New Approach for Liquid Biopsy and its Potential Clinical Implications. DOI 10.3389/fcell.2022.918795↗
- Marianne Sinn · 6 shared papers, 2022–2025 · strength 0.99
- Paper Patient-derived tumor organoids highlight the potential of precision medicine in managing pancreatic ductal adenocarcin… DOI 10.1002/ijc.35443↗
- Paper Identification and characterization of tumor and stromal derived liquid biopsy analytes in pancreatic ductal adenocarci… DOI 10.1186/s13046-024-03262-x↗
- Paper Tumor-Stroma Interaction in PDAC as a New Approach for Liquid Biopsy and its Potential Clinical Implications. DOI 10.3389/fcell.2022.918795↗
- Faik Güntac Uzunoglu · 6 shared papers, 2022–2025 · strength 0.99
- Paper Patient-derived tumor organoids highlight the potential of precision medicine in managing pancreatic ductal adenocarcin… DOI 10.1002/ijc.35443↗
- Paper Identification and characterization of tumor and stromal derived liquid biopsy analytes in pancreatic ductal adenocarci… DOI 10.1186/s13046-024-03262-x↗
- Paper Tumor-Stroma Interaction in PDAC as a New Approach for Liquid Biopsy and its Potential Clinical Implications. DOI 10.3389/fcell.2022.918795↗
- Jakob Robert Izbicki · 5 shared papers, 2022–2025 · strength 0.81
- Paper Patient-derived tumor organoids highlight the potential of precision medicine in managing pancreatic ductal adenocarcin… DOI 10.1002/ijc.35443↗
- Paper Identification and characterization of tumor and stromal derived liquid biopsy analytes in pancreatic ductal adenocarci… DOI 10.1186/s13046-024-03262-x↗
- Paper Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancre… DOI 10.1093/clinchem/hvac214↗
- Thilo Hackert · 2 shared papers, 2025 · strength 0.40
- Paper Patient-derived tumor organoids highlight the potential of precision medicine in managing pancreatic ductal adenocarcin… DOI 10.1002/ijc.35443↗
- Paper Identification and characterization of tumor and stromal derived liquid biopsy analytes in pancreatic ductal adenocarci… DOI 10.1186/s13046-024-03262-x↗
- Julian Götze · 2 shared papers, 2022–2025 · strength 0.37
- Paper Identification and characterization of tumor and stromal derived liquid biopsy analytes in pancreatic ductal adenocarci… DOI 10.1186/s13046-024-03262-x↗
- Paper Tumor-Stroma Interaction in PDAC as a New Approach for Liquid Biopsy and its Potential Clinical Implications. DOI 10.3389/fcell.2022.918795↗
- Cenap Güngör · 2 shared papers, 2021–2022 · strength 0.25
- Paper Characterization of RARRES1 Expression on Circulating Tumor Cells as Unfavorable Prognostic Marker in Resected Pancreat… DOI 10.3390/cancers14184405↗
- Paper A novel risk-scoring system conducing to chemotherapy decision for patients with pancreatic ductal adenocarcinoma after… DOI 10.7150/jca.57768↗
- Tabea Sturmheit · 1 shared paper, 2025 · strength 0.21
- Steven A. Johnsen · 1 shared paper, 2025 · strength 0.21
- Volker Spindler · 1 shared paper, 2025 · strength 0.19
- Kim C. Honselmann · 1 shared paper, 2025 · strength 0.19
- Louisa Stern · 1 shared paper, 2023 · strength 0.14
- Joseph Tintelnot · 1 shared paper, 2023 · strength 0.14
- Leonie Konczalla · 1 shared paper, 2022 · strength 0.14
- Dan Wang · 1 shared paper, 2021 · strength 0.12
- Yuqiang Li · 1 shared paper, 2021 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.